Overview

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether treatment with ST266 results in less scarring, in subjects with diabetes separately comparing healing of the skin graft and the skin graft donor site using ST266 plus a burn dressing versus placebo and a burn dressing.
Phase:
Phase 2
Details
Lead Sponsor:
Noveome Biotherapeutics, formerly Stemnion
Treatments:
Pharmaceutical Solutions